摘要
<正>The The β-galactosideα2-6-sialyltransferase 1(ST6Gal-I)is the principal sialyltransferase responsible for the addition ofα2-6-sialic acid to the termini N-glycans on cell surface.Although ST6Gal-I in cancer cell resistance to chemotherapeutics agents has been previously reported,the role of ST6Gal-I in clinical drug resistance of hepatocellular carcinoma(HCC)is not fully understood.In this study,we found that knockdown of ST6Gal-I increased the sensitivity of hepatocarcinoma MHCC97-H
引文